Two Molecules, One Mitochondrial Story

The short version

This page lines up NAD+ and MOTS-c on the dimensions that matter most when reading longevity research: what kind of molecule each is, where it has been studied, how strong the evidence is, what species the studies used, regulatory status, and the single most important caution for each. The headline is blunt: NAD+ has the deeper human evidence base — multiple RCTs showing blood NAD+ elevation, one study showing improved insulin sensitivity in humans — but its translation to hard clinical endpoints (disease prevention, longevity) remains genuinely unproven as of 2025 ^[1]. MOTS-c is earlier-stage, with compelling animal and mechanistic data and a promising human biomarker association, but no interventional human efficacy trials ^[9]. Neither is a proven anti-aging treatment. Both are subjects of serious ongoing research.

The comparison matrix

Molecular class and origin

NAD+ and MOTS-c are fundamentally different kinds of molecules, which is part of why comparing them is illuminating. NAD+ is not a peptide at all — it is a dinucleotide, a small molecule assembled from two nucleotides, that every cell on Earth produces through its own biosynthetic salvage pathway. Its role as an electron carrier places it at the absolute center of cellular metabolism ^[4]. MOTS-c, by contrast, is a peptide — a short chain of 16 amino acids — and an unusual one: encoded not in the nuclear genome but within the mitochondrial DNA, inside the 12S ribosomal RNA gene ^[10]. That two such different molecule types both converge on the same aging-biology theme — mitochondrial function and metabolic resilience — reflects how interconnected the cellular mechanisms of aging actually are.

Evidence base and species

The evidence base for the two is at different maturities, and in a different direction.

NAD+ (as precursors NMN and NR) has been tested in multiple human RCTs. Blood NAD+ elevation is the consistent, well-replicated human signal ^[2][5]. One carefully designed human study showed improved muscle insulin sensitivity ^[3]. A 2025 cardiac study with human myocardium showed a specific HMGCS2-dependent mechanism for NAD+ repletion in heart failure ^[7]. The limitation is that these findings are mechanistic or surrogate-endpoint outcomes; the leap to disease prevention or longevity in humans has not been made in controlled trials, and a 2025 authoritative review concluded human data remain limited and tissue-specific dynamics poorly characterized ^[1].

MOTS-c's human data point comes from the other direction: an observational finding that lower circulating MOTS-c in hemodialysis patients was independently associated with worse mortality and cardiovascular outcomes ^[9]. That is a compelling signal about endogenous MOTS-c as a biomarker, but says nothing about what exogenous MOTS-c does in humans. The efficacy data — the performance improvements in aged mice, the AMPK activation, the nuclear translocation — are all preclinical ^[8][11][12].

Regulatory and anti-doping status

The regulatory contrast is sharp and practically important. NAD+ and its precursors (NMN, NR) are sold as dietary supplements — not approved drugs, but commercially available over the counter in most jurisdictions, though NMN faces an FDA challenge to its supplement status ^[1]. NAD+ is not on WADA's prohibited list.

MOTS-c is at the opposite end of the regulatory spectrum. It is not approved for any human use, is sold only as a research chemical for laboratory use, and is treated as a prohibited substance in elite sport — covered under peptide and metabolic-modulator categories by anti-doping authorities including USADA and WADA ^[9]. An athlete testing positive for MOTS-c faces sanctions. These are not equivalent categories, and the distinction matters for anyone reading this desk for practical orientation.

Key caution for each

NAD+ supplementation's key caution is the gap between the intermediate endpoint (blood NAD+ rises) and the hard endpoint (health or longevity benefit). Multiple RCTs reliably show the former; the latter has not been demonstrated in controlled human trials, and the most current synthesis of the evidence says so plainly ^[1]. Additionally, the emerging concern about NAD+ in cancer biology — its dual, context-dependent roles — means individuals with active or prior cancer should not supplement without specific oncology guidance ^[4].

MOTS-c's key caution is simpler and harder: there are no human interventional trials, and there is no validated human pharmacokinetics. Every dose, every protocol, every community account of exogenous MOTS-c use occurs without a peer-reviewed human evidence base to anchor it ^[9][10]. That is a significant epistemic gap, and this desk does not attempt to fill it with animal-to-human extrapolation.